Matthew Galsky on Adjuvant Nivolumab Trials

(2:18)

Matthew Galsky Gives an Overview of Bladder Cancer

(1:35)

Breakthroughs in Bladder Cancer Immunotherapy, with Matthew Galsky

(44:28)

Matthew Galsky, MD, on how studies focused on genetic mutations impact prostate cancer treatment

(1:4)

Matthew Galsky, MD, shares a message for patients regarding clinical progress in bladder cancer

(1:8)

Management of Urothelial Bladder Cancer with Dr Matthew Galsky

(56:38)

Matthew Galsky, MD, elaborates on outcomes from the CheckMate 274 trial

(2:53)

Matthew Galsky, MD, on the role of PD-L1 testing in previously untreated, locally advanced or mUC

(3:31)

Dr. Matthew Galsky on Fatal Adverse Events Associated With mTOR Inhibitors

(2:)

Matthew Galsky, MD, considers a new standard of maintenance with the Javelin study outcomes

(42)

Matthew Galsky, MD, shares the design and outcomes of the Javelin Bladder 100 study

(2:12)

Matthew Galsky, MD, discusses how to identify patients that will likely be good responders for I-O

(2:14)

Matthew Galsky, MD, tells us about the design and outcomes of the EV-301 trial from ASCO GU '21

(2:1econd)

Dr. Matthew Galsky on PFS as an Endpoint in Urothelial Cancer Trials

(1:35)

Matthew Galsky, MD, on the CheckMate-274 study in high risk, muscle-invasive urothelial carcinoma

(2:36)

Matthew Galsky, MD, discusses the practice-changing potential of the PROfound study from ESMO 2020

(2:30)

Dr. Galsky on Progression on Immunotherapy in Bladder Cancer

(59)

Matthew Galsky, MD, considers the implications of the IMvigor130 clinical study

(1:58)

Matthew Galsky, MD, explains which biomarkers likely have the most predictive value

(1:45)

Matthew Galsky, MD, regarding Cohort 2 of the EV-201 trial presented at ASCO GU 2021

(2:1econd)